Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | CCR9 | P51686 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.52 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 3/20 | 0.51 |
| ▸ | CCR1 | P32246 | 2/20 | 0.51 |
| ▸ | CCR4 | P51679 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221343 | 0.91 | CCR9 (0.66) | ACLYMEN1KMT2AGAACCR9 | |
| SCHEMBL13146456 | 0.84 | CCR2 (0.62) | LMNAHTTCCR2 | |
| SCHEMBL3090152 | 0.82 | LMNA (0.70) | KMT2ACCR9LMNAHTTCCR2 | |
| SCHEMBL3078432 | 0.82 | LMNA (0.60) | ACLYKMT2ACCR9LMNAHTT | |
| SCHEMBL12221311 | 0.80 | CCR9 (0.82) | KMT2AKDM1ACCR9LMNAHTT | |
| SCHEMBL12221304 | 0.80 | CCR9 (0.66) | CCR9LMNAHTTCCR2 | |
| SCHEMBL13180354 | 0.79 | LMNA (0.56) | ACLYKMT2ACCR9LMNAHTT | |
| SCHEMBL7572164 | 0.79 | CCR2 (0.59) | ACLYMEN1KMT2AGAAKDM1A | |
| SCHEMBL2533357 | 0.78 | KMT2A (0.64) | ACLYMEN1KMT2AGAAKDM1A | |
| SCHEMBL2531458 | 0.77 | LMNA (0.69) | ACLYKMT2ACCR9LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | ACLY 3799/4885MEN1 4867/4885KMT2A 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.